Over the past weeks,
Bayer's shares have been on a roller coaster ride. A slide down to a
20-year low due to falling forecasted 2025 earnings and a
harsher than expected outlook has investors on edge. The
Q3 losses and a cautious outlook have compounded the worries. Investors are urging for
faster changes after the company's stock reached its lowest point in two decades. Compounding the company's crises are weak Q3 results, guidance cuts, a warning on
crop-sciences unit, and several legal battles. Despite a few
legal victories, more cases are being reopened, adding to the gloomy outlook. Bayer’s performance falls short of investor’s expectations with agtech venture into AI business with
Microsoft and acquisition of rights for a cardiovascular drug in Japan being the silver linings. Currently, shareholders are pressuring the CEO to rectify the continuous torrent of bad news.
BAYER Stocks News Analytics from Mon, 29 Jan 2024 08:00:00 GMT to Thu, 12 Dec 2024 07:53:57 GMT -
Rating -7
- Innovation -5
- Information 3
- Rumor -5
